Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4876 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-23

Study Completion Date

2017-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

NCT03555591

Type 2 Diabetes Mellitus

COMPLETED

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097

Type 2 Diabetes

COMPLETED PHASE1

A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes

NCT03761797

Diabetes Mellitus, Type 2

COMPLETED

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

NCT06579105

Diabetes Mellitus, Type 2

COMPLETED PHASE2

A Study Conducted Over 3 Periods to Look at the Drug in the Body

NCT01225939

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral antidiabetic drug (OAD)

OAD

Intervention Type DRUG

OAD except Trazenta tablets

Trazenta

Intervention Type DRUG

Linagliptin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OAD

OAD except Trazenta tablets

Intervention Type DRUG

Trazenta

Linagliptin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients with type 2 Diabetes Mellitus who have never been treated with Trazenta tablets / Linagliptin (monotherapy) before enrollment. (Trazenta group)
* Patients with type 2 Diabetes Mellitus starting any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug (OAD)) except Trazenta tablets. (OAD group)